Dyspepsia, which is defined as pain or discomfort centered in the upper abdomen, is encountered frequently in primary care and subspecialty practice.
Dyspepsia is a symptom complex caused by a heterogeneous group of disorders and diseases. A large fraction of patients with dyspepsia suffer from functional dyspepsia, in which no evidence of organic disease (typically on the basis of upper endoscopy) is found to explain persistent or recurrent symptoms.
Initial management strategies for uninvestigated dyspepsia include empiric antisecretory therapy, the “test-and-treat” strategy for Helicobacter pylori, or prompt upper endoscopy. The cost-effectiveness of empiric therapy versus the test-andtreat strategy is dependent upon a number of variables including the prevalence of H. pylori infection, ulcer prevalence, and likelihood that an ulcer is due to H. pylori infection. As the prevalence of H. pylori infection falls and the likelihood of H. pylori negative ulcer increases, empiric antisecretory therapy will become more cost-effective.
Upper endoscopy should be reserved for patients older than 45 to 50 years with symptom presentation and those with warning signs. Endoscopy also should be considered in those for whom empiric therapy or an attempt at the test-andtreat strategy fails.
Common-sense dietary counseling can be helpful in patients with meal-related symptoms. Highly restrictive diets rarely improve symptoms and may be counterproductive if nutrition is compromised.
KeywordsOmeprazole Pylorus Infection Dyspepsia Lansoprazole Esomeprazole
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.Talley NJ, Stanghellini V, Heading RC, et al.: Functional gastroduodenal disorders. In The Functional Gastrointestinal Disorders, edn 2. Edited by Drossman DA. McLean, VA: Degnon Associates; 2000:299–350. An excellent reference reflecting the efforts of international working teams. The book includes thorough literature reviews, proposed definitions for the functional gastrointestinal disorders, and recommendations for future research.Google Scholar
- 5.Lassen AT, Pedersen FM, Bytzer P, et al.: Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial. Lancet 2000, 356:455–460. Important randomized, controlled study of alternative strategies to manage uninvestigated dyspepsia.PubMedCrossRefGoogle Scholar
- 6.Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. Gut 1997, 41:8–13.Google Scholar
- 7.American Gastroenterological Association medical position statement: Evaluation of dyspepsia. Gastroenterology 1998, 114:579–558.Google Scholar
- 15.Delaney BC, Innes MA, Deeks J, et al.: Initial management strategies for dyspepsia. Cochrane Database Sys Rev 2000, 2:CD001961. A recent systematic review of 10 studies evaluating the effectiveness of PPIs, H2RAs, antacids, and early endoscopy in patients with uninvestigated dyspepsia.Google Scholar
- 16.Jones RH, Baxter G: Lansoprazole 30 mg daily versus ranitidine 150 b.d. in the treatment of acid-related dyspepsia in general practice 1997, 11:541–546.Google Scholar
- 26.Chey WD, Ladabaum U, Fendrick AM, Scheiman JM: Cost-effectiveness of empiric PPI therapy vs. test and treat in uninvestigated dyspepsia: impact of decreasing H. pylori prevalence and increasing non-H. pylori ulcers. Am J Gastroenterol 2001, 96:A836.Google Scholar
- 28.Physicians’ Desk Reference OnLine. Medical Economics Company, Inc; 2002. URL: www.pdr.net. Accessed January 27, 2002.Google Scholar
- 29.AHFS Drug Information 2001. Besthesda, MD: American Society of Health-System Pharmacists; 2001.Google Scholar
- 30.Drug Topics Red Book. Montvale, NJ: Medical Economics Company, Inc.; 2001.Google Scholar